PMID- 37861914
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231124
IS  - 1534-6269 (Electronic)
IS  - 1523-3790 (Linking)
VI  - 25
IP  - 11
DP  - 2023 Nov
TI  - Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large 
      B Cell Lymphoma.
PG  - 1387-1396
LID - 10.1007/s11912-023-01466-6 [doi]
AB  - PURPOSE OF REVIEW: We review the recent practice-changing trials of anti-CD19 
      chimeric antigen receptor (CAR) T cell therapies in large B cell lymphoma (LBCL) 
      including phase 3 comparisons with second-line standard-of-care (SOC) and phase 2 
      investigations in transplant-ineligible patients or as part of first-line 
      treatment. RECENT FINDINGS: ZUMA-7 found significantly improved overall survival 
      and event-free survival (EFS) with axicabtagene ciloleucel (axi-cel) versus SOC 
      of salvage chemotherapy followed by autologous stem-cell transplantation. This 
      represents the first such survival improvement in nearly 30 years for 
      early-relapsed or refractory (r/r) LBCL. TRANSFORM demonstrated prolonged EFS for 
      lisocabtagene maraleucel (liso-cel) versus SOC but BELINDA did not for 
      tisagenlecleucel. Second-line CAR T cell was a viable curative-intent therapy in 
      elderly (ZUMA-7; axi-cel) and/or transplant-ineligible (PILOT; liso-cel) 
      patients. ZUMA-12 demonstrated effectiveness for axi-cel as part of first-line 
      treatment for high-risk LBCL. These results support a role for CAR T cell therapy 
      as new second-line SOC for r/r LBCL and highlight its potential evolution into 
      future first-line treatment for high-risk disease.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Lionel, Anath C
AU  - Lionel AC
AD  - Division of Cancer Medicine, Department of Lymphoma and Myeloma, University of 
      Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Westin, Jason
AU  - Westin J
AUID- ORCID: 0000-0002-1824-2337
AD  - Division of Cancer Medicine, Department of Lymphoma and Myeloma, University of 
      Texas MD Anderson Cancer Center, Houston, TX, USA. jwestin@mdanderson.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231020
PL  - United States
TA  - Curr Oncol Rep
JT  - Current oncology reports
JID - 100888967
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Antigens, CD19
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy
MH  - Standard of Care
OTO - NOTNLM
OT  - Anti-CD19
OT  - CAR T cell
OT  - Early relapse
OT  - Large B cell lymphoma
OT  - Refractory disease
OT  - Second line
EDAT- 2023/10/20 12:42
MHDA- 2023/11/13 06:42
CRDT- 2023/10/20 11:12
PHST- 2023/09/14 00:00 [accepted]
PHST- 2023/11/13 06:42 [medline]
PHST- 2023/10/20 12:42 [pubmed]
PHST- 2023/10/20 11:12 [entrez]
AID - 10.1007/s11912-023-01466-6 [pii]
AID - 10.1007/s11912-023-01466-6 [doi]
PST - ppublish
SO  - Curr Oncol Rep. 2023 Nov;25(11):1387-1396. doi: 10.1007/s11912-023-01466-6. Epub 
      2023 Oct 20.